Research Article
Home-Based Transcutaneous Neuromodulation Improved Constipation via Modulating Gastrointestinal Hormones and Bile Acids
Table 2
The comparison of plasma bile acids among FC patients and control group. Median (quartile range), nonparametric test.
| Bile acids (ng/ml) | Before TN treatment (treatment group, ) | After TN treatment (treatment group, ) | Control group () |
| TUDCA | 0.00 (0.00~1.65) | 0.00 (0.00~6.22) | 1.02 (0.18~2.10) | TCDCA | 22.80 (7.33~55.60) | 36.80 (14.90~58.95) | 13.65 (7.38~47.45) | UDCA | 11.80 (5.23~36.30) | 26.00 (12.45~44.75) | 8.74 (2.68~33.78) | CDCA | 44.70 (19.15~44.70) | 98.00 (19.95~273.00) | 87.80 (21.60~283.35) | LCA | ND | ND | <5 | GCA | 43.50 (17.85~147.35) | 52.60 (23.30~106.00) | 16.95 (10.83~70.80) | GCDCA | 118.70 (56.05~491.10) | 188.20 (78.60~255.20) | 400.00 (90.25~677.50) | GDCA | 34.80 (9.41~89.05) | 20.60 (12.40~38.50) | 28.95 (11.33~52.43) | TDCA | 31.30 (11.85~60.05 | 12.64 (9.29~19.95 | 2.40 (1.85~4.63) | TCA | 67.60 (30.71~178.90 | 31.70 (12.54~72.90 | 2.45 (1.03~26.57) | TLCA | 4.10 (3.23~4.95 | 3.20 (2.09~3.70 | 1.05 (0.26~2.26) | CA | 18.70 (7.35~31.00) | 21.10 (13.60~33.00) | 28.70 (3.83~92.35) |
|
|
versus control group (Mann-Whitney U Test); versus treatment group before TN treatment (Wilcoxon Signed Ranks Test); ND, not detectable. |